Report: Immunotherapy of Cancer TOC

INTRODUCTION
- CONTRIBUTION OF THE STUDY AND FOR WHOM
- OBJECTIVES AND GOALS OF THE STUDY
- STUDY SCOPE AND FORMAT
- METHODOLOGY
- INFORMATION SOURCES
- AUTHOR' S CREDENTIALS
- RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
- DISCLAIMER
EXECUTIVE SUMMARY
- Summary Table:
- GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Summary Figure:
- GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
OVERVIEW
- DEFINITION AND ETIOLOGY OF CANCER
- CANCER STATISTICS
- Table 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
- Table 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
- Table 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
- Table 3 (CONTINUED)
  - IMMUNOTHERAPY OF CANCER
  - TYPES OF CANCER FOR WHICH IMMUNOTHERAPY TREATMENTS EXIST OR ARE LIKELY TO BE INTRODUCED BY 2012
    - BREAST CANCER
    - COLORECTAL CANCER
    - HEAD AND NECK CANCER
    - KIDNEY CANCER
    - LEUKEMIAS
      - Leukemias (Continued)
    - LIVER CANCER
    - LUNG CANCER
    - MALIGNANT MELANOMA
    - MULTIPLE MYELOMA
    - NONHODGKIN' S LYMPHOMA
    - OSTEOSARCOMA
    - OVARIAN CANCER
    - PANCREATIC CANCER
    - PROSTATE CANCER
    - STOMACH CANCER
  - CURRENT METHODS OF TREATMENT
    - SURGERY
    - RADIATION THERAPY
    - PHARMACEUTICAL THERAPY
    - IMMUNOTHERAPY
    - INFLAMMATORY RESPONSE
      - Cell-Mediated Immunity
      - Humoral Immunity
      - Macrophage Processing
      - Nonspecific Immunity
    - CYTOKINES
      - Two Types of Cytokines
    - MONOCYTES
    - PHAGOCYTES
    - SPECIFIC IMMUNITY
      - Lymphocytes
        
        B-Cells
        T-Cells
        NK Cells
    - CLINICAL APPROACHES TO IMMUNOTHERAPY
      - Passive Cellular Immunotherapy
        
        Dealing with Significant Toxicity
      - Passive Humoral Immunotherapy
      - Active Specific Immunotherapy
      - Nonspecific Immunotherapy
    - TYPES OF IMMUNOTHERAPY PRODUCTS
      - Biological Response Modifiers
- Table 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 6 (CONTINUED)
- Table 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
  - Colony Stimulating Factors
    - Treating Neutropenic Fevers
    - A Justified Expense
  - Interferons
    - A Family of Small Proteins
    - Anticancer Effects
    - Side Effects
    - Production of Interferon
    - Interferon-alpha
    - Interferon-beta
      - Interferon-Beta-1a
  - Interleukins
    - Interleukin-2
    - Other Infection-Fighting Cells
    - Side Effects
  - Tumor Necrosis Factor
- ANTIBODIES
  - ANTIBODY FORMS IN PRODUCTS
    - Abtides
    - Antibody Conjugates
    - Antiserums
    - Bispecific Antibodies
    - Camouflaged Antibodies
    - Chimeric Antibodies
    - Humanized Antibodies
    - Fully Human Antibodies
    - Progenitor Stem Cells
    - Single-Chain Antibodies
    - Synthetic Antibodies
  - VACCINES
    - ANTIGENS: THEIR ROLE IN CANCER VACCINES
    - VACCINE DEVELOPMENT STRATEGIES
    - A SUMMARY OF TWO APPROACHES: LOW-TECH VS. HIGH-TECH
  - TECHNOLOGY ADVANCES
PRODUCTS AND APPLICATIONS
- IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
- Table 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
  - MECHANISM OF ACTION OF SELECTED IMMUNOTHERAPY PRODUCTS
- Table 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
  - BIOLOGICAL RESPONSE MODIFIERS
    - THE MARKET FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER
- Table 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
  - COLONY STIMULATING FACTORS
    - MARKETED BRM PRODUCTS FOR THE TREATMENT OF CANCER
- Table 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
  - Aranesp
  - Granocyte
  - Leukine
  - Neorecormon
  - Neulasta/Neupopeg/Neupogen/Granulokine
  - Neumega
  - Procrit
  - Stemgen
  - The Market for Colony Stimulating Factors
- Table 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENT BY PRODUCT, THROUGH 2012 ($ MILLIONS)
  - The Market for Colony Stimulating Factors to Treat Cancer
- Table 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
  - Colony Stimulating Factors in Development
- INTERFERONS
  - Interferon-Alpha
    - Interferon Alpha-2b Products
  - Marketed Interferon Products for the Treatment of Cancer
- Table 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
  - Infergen
  - Intron A and PEG-Intron/Rebetron
    - PEG-Intron vs. Intron A
  - Multiferon
  - Roferon-A
- Interferon-Gamma
  - Actimmune/ Imukin
    - The Market for Interferon Products Used in the Treatment of Cancer
- Table 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
  - THE MARKET FOR interFErons TO TREAT CANCER
- Table 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
  - INTERLEUKINS
    - Marketed Interleukin Products for the Treatment of Cancer
- Table 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
  - ONTAK
  - PROLEUKIN
    - The Market for Interleukin Products for the Treatment of Cancer
- Table 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
  - TUMOR NECROSIS FACTOR INHIBITORS
  - BIOLOGICAL RESPONSE MODIFIERS IN DEVELOPMENT FOR THE TREAMENT OF CANCER
- Table 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
  - Actimmune
  - Cintrekedin Besudotox
  - Multikine
    - Clinical Trial Results
    - A Coca-Cola Formula
  - PEG-Intron
  - PRX321
  - Virulizin
- COMBINATION CYTOKINE-ANTIBODY TECHNOLOGY IN DEVELOPMENT
- MONOCLONAL ANTIBODY PRODUCTS
- Table 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
- Table 20 (CONTINUED)
  - MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
    - Avastin
      - Avastin (Continued)
      - Avastin (Continued)
      - The Avastin Advantage
      - Medicare Reimbursement Law Supports Use of Avastin
    - Bexxar
      - Bexxar (Continued)
    - Campath/ MabCampath
    - Erbitux
- Table 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
- Table 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
  - Erbitux (Continued)
  - Herceptin
  - Mylotarg
  - Panorex
  - Rituxan/MabThera
    - Rituxan/Mabthera (Continued)
  - Vectibix
  - Zevalin
    - First Radioimmunotherapeutic Drug
    - Results of Trials
    - Sales of Zevalin
- THE MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR ALL INDICATIONS
  - Monoclonal Antibody Sales by Technology
- Table 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
  - Monoclonal Antibody Sales by Target
- Table 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
  - THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES TO TREAT CANCER
- Table 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
- Table 25 (CONTINUED)
  - THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
- Table 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
- Table 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
- Figure 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
  - MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT FOR THE treatment of cancer
- Table 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
- Table 28 (CONTINUED)
- Table 28 (CONTINUED)
  - Abegrin (formerly Vitaxin)
  - Avastin
  - Campath/MabCampath
  - CP-675,206
  - Denosumab
  - Herceptin
  - HuMax-CD4
  - HuMax-CD20
  - HuMax-EGFr
  - MDX-010
  - Nimotuzumab
  - OvaRex
  - Pemtumomab
  - Rencarex
  - Rituxan/MabThera
- VACCINES
- Table 29 TUMOR ANTIGENS USED IN CANCER VACCINES
  - TYPES OF CANCER VACCINES
    - Whole-cell Vaccines
    - Antigen/Adjuvant Vaccines
    - Idiotype Vaccines
    - Autologous versus Allogenic Vaccines
    - Dendritic Cell Vaccines
    - Synthetic Cell Protein Antigens
    - Gangliosides
    - Heat Shock Proteins
  - CANCER VACCINES ON THE WORLDWIDE MARKET
    - Gardasil
    - M-Vax
    - Melacine
    - OncoVax
  - THE MARKET FOR CANCER VACCINES
- Table 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
- Table 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
- Figure 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)
  - CANCER VACCINES IN DEVELOPMENT
- Table 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
- Table 32 (CONTINUED)
- Table 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
  - Allovectin-7
    - Allovectin-7 (Continued)
  - BiovaxID
  - Cervarix
  - DCVax-Brain
  - DCVax-Prostate
  - GMK
  - GVAX Prostate Vaccine
  - IGN101
  - Insegia
    - Insegia (Continued)
    - Insegia (Continued)
  - M-Vax
  - Melacine
  - MyVax Personalized Immunotherapy
    - Myvax Personalized ... (Continued)
  - Oncophage
  - OncoVax
  - Panvac-VF
  - Sipuleucel-T
  - Stimuvax
  - TG 4001
  - TG 1042
  - Theratope
- OTHER IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER
  - MARKETED PRODUCTS
    - Gleevec
    - Iressa
    - Nexavar
    - Revlimid
    - Sprycel
    - Sutent
    - Tarceva
    - Thalomid
    - Velcade
    - The Market for Other Immunotherapy Products for the Treatment of Cancer
- Table 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
  - PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF CANCER
- Table 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
- Table 28 (CONTINUED)
- Table 28 (CONTINUED)
  - Advexin
  - BAY 43-9006
  - Ceplene
  - Dacogen
  - Efaproxyn
  - Genasense
  - Hycamptin
  - INGN 241
  - Junovan
  - Nexavar
  - Onconase
  - Orathecin
  - Pixantrone
  - PTK787
  - Telcyta
  - Thymitaq
  - Torisel
  - Tykerb/Tycerb
  - Velcade
  - Zarnestra
    - Zarnestra (Continued)
INDUSTRY
- BLOCKBUSTER DRUGS ON THE WORLDWIDE PHARMACEUTICAL MARKET APPROACH 100
- U.S. PHARMACEUTICAL INDUSTRY GROWTH TO INCREASE SLIGHTLY
- MORE MERGERS, ACQUISITIONS AND LICENSING
  - MORE MERGERS, ACQUISITIONS AND ... (Continued)
- BIOGENERICS-THE NEXT REVOLUTION
  - BIOGENERICS-THE NEXT ... (Continued)
COMPANY PROFILES
- ABGENIX, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
    - XenoMouse and XenoMax Technologies
    - Technology Advantages
      - Technology Advantages (Continued)
  - CORPORATE STRATEGY
- ALFACELL CORPORATION
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- AMGEN, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 36 AMGEN' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
- ANTIGENICS INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 37 ANTIGENICS' PRODUCT PIPELINE
  - CORPORATE STRATEGY
- AVAX TECHNOLOGIES, INC.
  - BUSINESS OVERVIEW
  - PRODUCTS
  - CORPORATE STRATEGY
- BIOGEN IDEC, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- BIOMIRA INC.
  - EDMONTON R&D PARK
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- CHIRON CORPORATION
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- GENENTECH, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- Table 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
- Table 38 (CONTINUED)
- Table 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
  - GENMAB A/S
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
    - CORPORATE STRATEGY
  - GENZYME CORPORATION
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
    - CORPORATE STRATEGY
  - GLAXOSMITHKLINE PLC
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
  - IMCLONE SYSTEMS, INC.
    - BUSINESS OVERVIEW
    - FINANCIAL INFORMATION
    - PRODUCTS
- Table 40 IMCLONE SYSTEMS' PRODUCT PIPELINE
  - CORPORATE STRATEGY
- IMMUNOMEDICS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 41 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE
- Table 41 (CONTINUED)
  - CORPORATE STRATEGY
- MEDAREX, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 42 MEDAREX' S PRODUCT PIPELINE
  - CORPORATE STRATEGY
- MEDIMMUNE, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
    - Leading Products (Continued)
- Table 43 MEDIMMUNE' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
- MERCK & COMPANY, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- MILLENNIUM PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 44 MILLENNIUM' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
- NORTHWEST BIOTHERAPEUTICS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 45 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE
  - CORPORATE STRATEGY
- PFIZER CORPORATION
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
    - Corporate Strategy (Continued)
- PROGENICS PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
- Table 46 PROGENICS' PRODUCT PIPELINE
  - CORPORATE STRATEGY
  - PROTEIN DESIGN LABS
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 47 PROTEIN DESIGN LABS' PRODUCTS IN PHASE II OR LATER
  - CORPORATE STRATEGY
- TRANSGENE S/A
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- VIREXX MEDICAL CORPORATION
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
LIST OF TABLES
- Summary Table:
- GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Table 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
- Table 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
- Table 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
- Table 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
- Table 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
- Table 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
- Table 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
- Table 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Table 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
- Table 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENTBY PRODUCT, THROUGH 2012 ($ MILLIONS)
- Table 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Table 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
- Table 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
- Table 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Table 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
- Table 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
- Table 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
- Table 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
- Table 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
- Table 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
- Table 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
- Table 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
- Table 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
- Table 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
- Table 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
- Table 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
- Table 29 TUMOR ANTIGENS USED IN CANCER VACCINES
- Table 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
- Table 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
- Table 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
- Table 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
- Table 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
- Table 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
- Table 36 AMGEN' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
- Table 37 ANTIGENICS' PRODUCT PIPELINE
- Table 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
- Table 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
- Table 40 IMCLONE SYSTEMS' PRODUCT PIPELINE
- Table 41 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE
- Table 42 MEDAREX' S PRODUCT PIPELINE
- Table 43 MEDIMMUNE' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
- Table 44 MILLENNIUM' S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
- Table 45 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE
- Table 46 PROGENICS' PRODUCT PIPELINE
- Table 47 PROTEIN DESIGN LABS' PRODUCTS IN PHASE II OR LATER
LIST OF FIGURES
- Summary Figure:
- GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
- Figure 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
- Figure 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)

Immunotherapy of Cancer

Table of Contents